Neel H B, Pearson G R, Weiland L H, Taylor W F, Goepfert H H, Pilch B Z, Lanier A P, Huang A T, Hyams V J, Levine P H, Henle G, Henle W
Laryngoscope. 1980 Dec;90(12):1981-90. doi: 10.1288/00005537-198012000-00009.
Sixty-three serum specimens from American patients with nasopharyngeal carcinoma were examined for antibodies to antigens associated with Epstein-Barr virus (EBV) and compared with 98 specimens from patients with other head and neck cancers, 133 from patients with benign head and neck diseases, and 96 from healthy donors. The level of antibody titers to EBV-associated antigens was correlated with nasopharyngeal carcinoma. The anti-EBV profile of elevated antibody titers directed against viral capsid antigen and early antigen was seen in undifferentiated and nonkeratinizing tumors but usually not in squamous cell tumors. Titers tended to rise with large increases in total tumor burden caused by distant metastases, often before clinical evidence of metastases. At the time of diagnosis, antibody-dependent cellular cytotoxicity testing was performed on serum samples from 46 of the patients with nasopharyngeal carcinoma. Pretreatment titers were usually low in patients in whom recurrence developed and were high in most of the patients who had a good response to treatment and have remained free of recurrence.
对63份来自美国鼻咽癌患者的血清标本进行检测，以查找与爱泼斯坦-巴尔病毒（EBV）相关抗原的抗体，并与98份来自其他头颈癌患者的标本、133份来自头颈良性疾病患者的标本以及96份来自健康供者的标本进行比较。针对EBV相关抗原的抗体滴度水平与鼻咽癌相关。在未分化和非角化肿瘤中可见针对病毒衣壳抗原和早期抗原的抗体滴度升高的抗EBV谱型，但在鳞状细胞肿瘤中通常未见。随着远处转移导致肿瘤总负荷大幅增加，滴度往往会升高，通常在转移的临床证据出现之前。在诊断时，对46例鼻咽癌患者的血清样本进行了抗体依赖性细胞毒性检测。复发患者的治疗前滴度通常较低，而对治疗反应良好且未复发的大多数患者的滴度较高。
